TP53 mutation and survival in chronic lymphocytic leukemia
Purpose - The precise prognostic impact of TP53 mutation and its incorporation into treatment algorithms in chronic lymphocytic leukemia (CLL) is unclear. We set out to define the impact of TP53 mutations in CLL. - Patients and Methods - We assessed TP53 mutations by denaturing high-performance liqu...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 10, 2010
|
| In: |
Journal of clinical oncology
Year: 2010, Volume: 28, Issue: 29, Pages: 4473-4479 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2009.27.8762 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.2009.27.8762 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.2009.27.8762 
|
| Author Notes: | Thorsten Zenz, Barbara Eichhorst, Raymonde Busch, Tina Denzel, Sonja Häbe, Dirk Winkler, Andreas Bühler, Jennifer Edelmann, Manuela Bergmann, Georg Hopfinger, Manfred Hensel, Michael Hallek, Hartmut Döhner, and Stephan Stilgenbauer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1885513690 | ||
| 003 | DE-627 | ||
| 005 | 20240703163855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240410s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2009.27.8762 |2 doi | |
| 035 | |a (DE-627)1885513690 | ||
| 035 | |a (DE-599)KXP1885513690 | ||
| 035 | |a (OCoLC)1443668582 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Zenz, Thorsten |d 1970- |e VerfasserIn |0 (DE-588)114963738 |0 (DE-627)577184202 |0 (DE-576)180278266 |4 aut | |
| 245 | 1 | 0 | |a TP53 mutation and survival in chronic lymphocytic leukemia |c Thorsten Zenz, Barbara Eichhorst, Raymonde Busch, Tina Denzel, Sonja Häbe, Dirk Winkler, Andreas Bühler, Jennifer Edelmann, Manuela Bergmann, Georg Hopfinger, Manfred Hensel, Michael Hallek, Hartmut Döhner, and Stephan Stilgenbauer |
| 264 | 1 | |c October 10, 2010 | |
| 300 | |b Diagramme | ||
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online ahead of print: August 9, 2010 | ||
| 500 | |a Gesehen am 10.04.2024 | ||
| 520 | |a Purpose - The precise prognostic impact of TP53 mutation and its incorporation into treatment algorithms in chronic lymphocytic leukemia (CLL) is unclear. We set out to define the impact of TP53 mutations in CLL. - Patients and Methods - We assessed TP53 mutations by denaturing high-performance liquid chromatography (exons 2 to 11) in a randomized prospective trial (n = 375) with a follow-up of 52.8 months (German CLL Study Group CLL4 trial; fludarabine [F] v F + cyclophosphamide [FC]). - Results - We found TP53 mutations in 8.5% of patients (28 of 328 patients). None of the patients with TP53 mutation showed a complete response. In patients with TP53 mutation, compared with patients without TP53 mutation, median progression-free survival (PFS; 23.3 v 62.2 months, respectively) and overall survival (OS; 29.2 v 84.6 months, respectively) were significantly decreased (both P < .001). TP53 mutations in the absence of 17p deletions were found in 4.5% of patients. PFS and OS for patients with 17p deletion and patients with TP53 mutation in the absence of 17p deletion were similar. Multivariate analysis identified TP53 mutation as the strongest prognostic marker regarding PFS (hazard ratio [HR] = 3.8; P < .001) and OS (HR = 7.2; P < .001). Other independent predictors of OS were IGHV mutation status (HR = 1.9), 11q deletion (HR = 1.9), 17p deletion (HR = 2.3), and FC treatment arm (HR = 0.6). - Conclusion - CLL with TP53 mutation carries a poor prognosis regardless of the presence of 17p deletion when treated with F-based chemotherapy. Thus, TP53 mutation analysis should be incorporated into the evaluation of patients with CLL before treatment initiation. Patients with TP53 mutation should be considered for alternative treatment approaches. | ||
| 700 | 1 | |a Eichhorst, Barbara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Busch, Raymonde |e VerfasserIn |4 aut | |
| 700 | 1 | |a Denzel, Tina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Häbe, Sonja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Winkler, Dirk |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bühler, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Edelmann, Jennifer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bergmann, Manuela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hopfinger, Georg |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hensel, Manfred |d 1964- |e VerfasserIn |0 (DE-588)1065849729 |0 (DE-627)816878307 |0 (DE-576)425541908 |4 aut | |
| 700 | 1 | |a Hallek, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Döhner, Hartmut |d 1957- |e VerfasserIn |0 (DE-588)110666585 |0 (DE-627)729880842 |0 (DE-576)375358846 |4 aut | |
| 700 | 1 | |a Stilgenbauer, Stephan |d 1966- |e VerfasserIn |0 (DE-588)114728380 |0 (DE-627)590333151 |0 (DE-576)302364781 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 28(2010), 29 vom: Okt., Seite 4473-4479 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a TP53 mutation and survival in chronic lymphocytic leukemia |
| 773 | 1 | 8 | |g volume:28 |g year:2010 |g number:29 |g month:10 |g pages:4473-4479 |g extent:7 |a TP53 mutation and survival in chronic lymphocytic leukemia |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.2009.27.8762 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.2009.27.8762 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240410 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 114963738 |a Zenz, Thorsten |m 114963738:Zenz, Thorsten |p 1 |x j | ||
| 999 | |a KXP-PPN1885513690 |e 450968729X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Published online ahead of print: August 9, 2010","Gesehen am 10.04.2024"],"name":{"displayForm":["Thorsten Zenz, Barbara Eichhorst, Raymonde Busch, Tina Denzel, Sonja Häbe, Dirk Winkler, Andreas Bühler, Jennifer Edelmann, Manuela Bergmann, Georg Hopfinger, Manfred Hensel, Michael Hallek, Hartmut Döhner, and Stephan Stilgenbauer"]},"recId":"1885513690","origin":[{"dateIssuedDisp":"October 10, 2010","dateIssuedKey":"2010"}],"person":[{"family":"Zenz","given":"Thorsten","display":"Zenz, Thorsten","role":"aut"},{"display":"Eichhorst, Barbara","role":"aut","family":"Eichhorst","given":"Barbara"},{"given":"Raymonde","family":"Busch","role":"aut","display":"Busch, Raymonde"},{"display":"Denzel, Tina","role":"aut","family":"Denzel","given":"Tina"},{"display":"Häbe, Sonja","role":"aut","family":"Häbe","given":"Sonja"},{"family":"Winkler","given":"Dirk","display":"Winkler, Dirk","role":"aut"},{"given":"Andreas","family":"Bühler","role":"aut","display":"Bühler, Andreas"},{"family":"Edelmann","given":"Jennifer","display":"Edelmann, Jennifer","role":"aut"},{"display":"Bergmann, Manuela","role":"aut","family":"Bergmann","given":"Manuela"},{"display":"Hopfinger, Georg","role":"aut","family":"Hopfinger","given":"Georg"},{"display":"Hensel, Manfred","role":"aut","family":"Hensel","given":"Manfred"},{"role":"aut","display":"Hallek, Michael","given":"Michael","family":"Hallek"},{"given":"Hartmut","family":"Döhner","role":"aut","display":"Döhner, Hartmut"},{"display":"Stilgenbauer, Stephan","role":"aut","family":"Stilgenbauer","given":"Stephan"}],"language":["eng"],"relHost":[{"title":[{"title_sort":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology"}],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"corporate":[{"role":"isb","display":"American Society of Clinical Oncology"}],"disp":"TP53 mutation and survival in chronic lymphocytic leukemiaJournal of clinical oncology","note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"part":{"text":"28(2010), 29 vom: Okt., Seite 4473-4479","issue":"29","pages":"4473-4479","year":"2010","extent":"7","volume":"28"},"pubHistory":["1.1983 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"zdb":["2005181-5"],"issn":["1527-7755"],"eki":["313116962"]},"origin":[{"dateIssuedKey":"1983","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-"}],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"recId":"313116962"}],"title":[{"title_sort":"TP53 mutation and survival in chronic lymphocytic leukemia","title":"TP53 mutation and survival in chronic lymphocytic leukemia"}],"id":{"doi":["10.1200/JCO.2009.27.8762"],"eki":["1885513690"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"7 S.","noteIll":"Diagramme"}]} | ||
| SRT | |a ZENZTHORSTTP53MUTATI1020 | ||